+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Secondary Hyperparathyroidism (Hormonal Disorders) - Drugs in Development, 2021

  • ID: 5331187
  • Drug Pipelines
  • March 2021
  • Region: Global
  • Global Markets Direct

FEATURED COMPANIES

  • Amgen Inc
  • Cinkate Corp
  • EA Pharma Co Ltd
  • Lupin Ltd
  • Novadiol Inc
  • OPKO Health Inc
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Secondary Hyperparathyroidism - Drugs in Development, 2021, provides an overview of the Secondary Hyperparathyroidism (Hormonal Disorders) pipeline landscape.

Secondary hyperparathyroidism is occurs when the parathyroid glands in neck produce too much parathyroid hormone (PTH) because calcium levels are too low. Symptoms include bone deformities, broken bones, swollen joints and chronic kidney failure. Treatment includes calcimimetic and hormone replacement therapy.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Secondary Hyperparathyroidism - Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Secondary Hyperparathyroidism (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Secondary Hyperparathyroidism (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Secondary Hyperparathyroidism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 2, 2, 1, 3 and 3 respectively.

Secondary Hyperparathyroidism (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Secondary Hyperparathyroidism (Hormonal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Secondary Hyperparathyroidism (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Secondary Hyperparathyroidism (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Secondary Hyperparathyroidism (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Secondary Hyperparathyroidism (Hormonal Disorders)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Secondary Hyperparathyroidism (Hormonal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Secondary Hyperparathyroidism (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Amgen Inc
  • Cinkate Corp
  • EA Pharma Co Ltd
  • Lupin Ltd
  • Novadiol Inc
  • OPKO Health Inc
  • MORE
Introduction
  • Report Coverage
Secondary Hyperparathyroidism - Overview

Secondary Hyperparathyroidism - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
Secondary Hyperparathyroidism - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Secondary Hyperparathyroidism - Companies Involved in Therapeutics Development
  • Amgen Inc
  • Cinkate Corp
  • EA Pharma Co Ltd
  • Lupin Ltd
  • Mitsubishi Tanabe Pharma Corp
  • Novadiol Inc
  • OPKO Health Inc
  • Scohia Pharma Inc
  • TaiRx Inc
  • Vidasym Inc
Secondary Hyperparathyroidism - Drug Profiles

calcifediol ER - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
cinacalcet - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
CK-15 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
CTA-091 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Dendocrin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
etelcalcetide hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
evocalcet - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
LNP-1892 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
SCO-006 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
upacicalcet - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
VS-105 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Secondary Hyperparathyroidism - Dormant Projects
  • Secondary Hyperparathyroidism - Discontinued Products
Secondary Hyperparathyroidism - Product Development Milestones
  • Featured News & Press Releases
  • Dec 21, 2020: Launch of Parsabiv intravenous injection syringe for dialysis, a calcimimetic agent in Japan
  • Jun 29, 2020: ONO receives manufacturing and marketing approval in Japan for Parsabiv intravenous injection syringe for dialysis, a calcimimetic agent
  • Mar 25, 2020: OPKO Health reports interim results for two ongoing RAYALDEE studies
  • Sep 04, 2018: OPKO initiates RAYALDEE phase 2 trial in dialysis patients
  • Jul 16, 2018: OPKO Partner Vifor Fresenius Receives Marketing Approval for RAYALDEE in Canada
  • May 22, 2018: Kyowa Hakko Kirin Launches ORKEDIA TABLETS (Evocalcet) for the Treatment of Secondary Hyperparathyroidism in Patients on Maintenance Dialysis in Japan
  • Mar 23, 2018: Kyowa Hakko Kirin Receives Approval for ORKEDIA Tablets (Evocalcet) for the Treatment of Secondary Hyperparathyroidism in Patients on Maintenance Dialysis in Japan
  • Nov 06, 2017: Kyowa Hakko Kirin Presented Results of Japan Phase III Clinical Study of Evocalcet at Kidney Week 2017 of the American Society of Nephrology
  • Jun 22, 2017: OPKO Health Announces KDIGO Clinical Practice Guideline Update on CKD-MBD
  • Jun 05, 2017: OPKO Health Provides Commercial Update for RAYALDEE
  • Apr 27, 2017: Kyowa Hakko Kirin Submits Application for Approval of Evocalcet (KHK7580) for Secondary Hyperparathyroidism in Maintenance Dialysis Patients in Japan
  • Feb 15, 2017: Launch of PARSABIV Intravenous Injection for Dialysis, a Calcimimetic Agent, for Treatment of Secondary Hyperparathyroidism in Patients on Hemodialysis
  • Feb 07, 2017: OPKO Health Promotes Thomas Nusbickel to Renal Division Chief Commercial Officer
  • Feb 07, 2017: FDA Approves Amgen's Parsabiv (Etelcalcetide), First New Treatment In More Than A Decade For Secondary Hyperparathyroidism In Adult Patients On Hemodialysis
  • Jan 31, 2017: Kyowa Hakko Kirin Announces Top-Line Results of Phase 3 Clinical Study of KHK7580 with Secondary Hyperparathyroidism in Japan
Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Number of Products under Development for Secondary Hyperparathyroidism, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Secondary Hyperparathyroidism - Pipeline by Amgen Inc, 2021
  • Secondary Hyperparathyroidism - Pipeline by Cinkate Corp, 2021
  • Secondary Hyperparathyroidism - Pipeline by EA Pharma Co Ltd, 2021
  • Secondary Hyperparathyroidism - Pipeline by Lupin Ltd, 2021
  • Secondary Hyperparathyroidism - Pipeline by Mitsubishi Tanabe Pharma Corp, 2021
  • Secondary Hyperparathyroidism - Pipeline by Novadiol Inc, 2021
  • Secondary Hyperparathyroidism - Pipeline by OPKO Health Inc, 2021
  • Secondary Hyperparathyroidism - Pipeline by Scohia Pharma Inc, 2021
  • Secondary Hyperparathyroidism - Pipeline by TaiRx Inc, 2021
  • Secondary Hyperparathyroidism - Pipeline by Vidasym Inc, 2021
  • Secondary Hyperparathyroidism - Dormant Projects, 2021
  • Secondary Hyperparathyroidism - Discontinued Products, 2021
List of Figures
  • Number of Products under Development for Secondary Hyperparathyroidism, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Targets, 2021
  • Number of Products by Stage and Targets, 2021
  • umber of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021
Note: Product cover images may vary from those shown
  • Amgen Inc
  • Cinkate Corp
  • EA Pharma Co Ltd
  • Lupin Ltd
  • Mitsubishi Tanabe Pharma Corp
  • Novadiol Inc
  • OPKO Health Inc
  • Scohia Pharma Inc
  • TaiRx Inc
  • Vidasym Inc
Note: Product cover images may vary from those shown
Adroll
adroll